Showing 1-10 of about 10 articles.
CollabRx, Inc.
CollabRx and GeneInsight to Collaborate on Interpretation and Reporting Service for Clinical Genetic Sequencing
SAN FRANCISCO and BOSTON, May 8, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing the clinical interpretation of molecular diagnostic testing, and GeneInsight LLC., a leading developer of software to support knowledge management and reporting for genetic testing laboratories, today announced an agreement to deliver a unique medical informatics solution to support the interpretation and reporting of genetic variants from sequencing-based tests.
CollabRx, Inc.
CollabRx Partners With Sengenics for Molecular Diagnostics
SAN FRANCISCO, April 9, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), today announced a partnership with Sengenics, a leading genetic diagnostics company, to provide turn-key diagnostic decision making solutions for Asian and global markets. Sengenics plans to incorporate CollabRx's interpretive content resources into its molecular cancer diagnostics tests and reports.
CollabRx, Inc.
CollabRx and OncoDNA Partner in Molecular Diagnostics
SAN FRANCISCO, April 4, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA's cancer mutation panels.
CollabRx, Inc.
CollabRx Forms Pan Cancer Molecular Oncology Editorial Board
SAN FRANCISCO, March 26, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced the formation of a Pan Cancer (biomarker-focused) molecular oncology editorial board to be led by Razelle Kurzrock, M.D., who will serve as Chief Editor.
CollabRx, Inc.
CollabRx(TM) and Projects In Knowledge(R) Partner to Provide Decision Support Tools to Oncologists
SAN FRANCISCO, March 4, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Projects In Knowledge, Inc., a leading developer of point-of-care digital and mobile information tools and continuing medical education (CME/CE) programs, today announced a multi-year partnership agreement to jointly distribute informational point-of-care software applications to the more than 35,000 oncologists and other clinicians in the Projects In Knowledge clinician network.
CollabRx, Inc.
CollabRx Forms Editorial Board for Prostate Cancer
SAN FRANCISCO, Feb. 19, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX) today announced the formation of an editorial board for prostate cancer to be led by E. David Crawford, M.D. who will serve as Chief Editor. Dr. Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher who has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, and one of the Top 20 Urologists in the country by Men's Health Magazine. Dr. Crawford will lead a distinguished group of physicians from leading institutions such as Yale University, University of Michigan, Cleveland Clinic, Dana-Farber Cancer Institute, and others. The complete editorial board can be found on the company's website (
CollabRx, Inc.
CollabRx Releases Second Generation Lung Cancer Clinical Decision Support Tool for Oncologists
SAN FRANCISCO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX) today announced the release of a new version of its Therapy Finder™application ("app") for lung cancer. The lung cancer Therapy Finder™app is a web-based decision support tool that enables oncologists to take into account the genetics of a patient's tumor when determining a treatment plan. The newest lung cancer Therapy Finder™ is currently freely available at the company's website and via distribution partners such as MedPage Today, Everyday Health's physician portal (
Showing 1-10 of about 10 articles.